Document:

Document

Exhibit 10.22
Execution Copy

												
	
			
		1 City Centre Drive
Suite #300
Mississauga, ON
L5B 1M2	Telephone:	(905) 275-6600
			Fax:	(905) 615-8128
				www.gwlra.com
				

February 11, 2019
MedAvail Technologies Inc
c/o CBRE Limited
5935 Airport Road, Suite 700
Mississauga, ON
L4V 1W5
Attention: John Potter
Dear John:
						
	Re:	Lease dated August 13, 2012 (as amended from time to time) (the “Lease”)
For Unit 1 consisting of approx. 16,595 square feet (the “Premises”)
Located at 6665 Millcreek Drive, Mississauga, ON L5N 5M4 (the “Building")

Pursuant to the Industrial Lease dated August 13, 2012 (the "Existing Lease”) made between The Great-West Life Assurance Company and 801611 Ontario Limited (collectively, the “Landlord”) and MedAvail Technologies Inc. (formerly Novarex Canada Inc.) (the "Tenant"), the Tenant leased from the Landlord certain premises designated as Unit 1 comprising a rentable area of approximately 16,595 square feet located on the ground floor of the building known municipally as 6665 Millcreek Drive, Mississauga, Ontario, outlined below are the terms and conditions for an extension of the Term of the Lease for the Premises (the “Offer”):
1.LANDLORD: The Great-West Life Assurance Company and 801611 Ontario Limited (the "Landlord")
2.TENANT: MedAvail Technologies Inc. (the “Tenant”)
3.EXTENSION OF TERM: The Term shall be extended for a period of two (2) years commencing on December 1, 2019 (the “Effective Date”) and ending on November 30, 2021 (the “Extension of Term”).
Except as otherwise included herein, the Tenant acknowledges that it has no further options to renew the Lease or extend the Term.
4.BASE RENT: The Base Rent shall be calculated in accordance with the Lease at the following annual rates per square foot of the Rentable Area of the Premises:
From December 1, 2019 to November 30, 2021 the rate of $9.25 per square foot
Unless otherwise required by the Landlord, the Tenant will pay to the Landlord all monthly instalments of Base Rent and Additional Rent, plus applicable taxes, required to be paid by the Tenant under the Lease, in advance, as per the Existing Lease.
5.DEPOSIT: Within 2 business days of the unconditional acceptance of this Offer, the Tenant shall pay

Page 2

to the Landlord the sum of $2,637.11 to be held by the Landlord, together with the Tenant’s existing deposit in the amount of $20,490.79, without interest, as a security deposit in respect of the Tenant's obligations under this Offer and the Lease. If the Tenant complies with all of its obligations under the Lease, the Landlord shall refund the security deposit within a reasonable time after the expiry of the Term or any renewal or extension thereof. In the event of any renewal or extension of the Term, the Tenant covenants and agrees to pay to the Landlord an amount necessary to increase the security deposit to an amount equal to the aggregate of 1 month Base Rent for the last year of the renewal or extension term plus 1 months estimated Additional Rent for the calendar year in which the extension or renewal term occurs.
6.CONDITION OF PREMISES: The Tenant shall accept the Premises "as is, where is" in their state and condition existing at the Effective Date.
The Landlord will, at its expense, complete the Landlord’s Work, if any, in accordance with the attached Schedule A.
The Tenant will, at its expense, complete the Tenant’s Work in accordance with the attached Schedule A.
7.LEASE AMENDMENTS: Save as expressly provided to the contrary in this Offer, reference to any rights to early occupancy, rent free periods or requirement on the Landlord's part, set out in the Lease, to perform any work or to pay to the Tenant any construction allowance, inducement, loan or other amount in connection with the Lease or improvements installed in the Premises shall not apply to the Extension of Term, such rights being deemed to have expired with the expiry of the initial Term of the Lease. Without limiting the generality of the foregoing, the following provisions shall be deleted from the Lease: Rent free/ Allowance.
8.DOCUMENTATION: The Tenant will execute a lease extension and amending agreement, prepared by the Landlord, incorporating the provisions of this Offer within 7 business days after receipt thereof, or within such reasonable time period as agreed upon by the Landlord and Tenant, prior to the Effective Date, failing which, this Offer shall be null and void at the Landlord's sole option. Save and except as set out in this Offer, all other terms and conditions of the Lease shall continue to apply and remain in full force and effect, including, without limitation, any reference in the Lease to generally accepted accounting principles, which shall refer to accounting practices generally accepted in the real estate industry in Canada. The Tenant will, upon request, execute concurrently with the execution of the lease extension and amending agreement, an attornment agreement required by the Landlord’s lenders, if any.
Upon execution of the lease extension and amending agreement, all provisions contained in this Offer shall merge with the existing Lease, as extended and amended, such that the existing Lease, as extended and amended, will supersede this Offer and all previous negotiations, brochures and information conveyed, whether oral or in writing between the parties or their representatives.
9.NO REPRESENTATIONS, ETC.: No agreement, representations, warranties or conditions relating in any way to the Premises, the Building, other tenants or prospective tenants or the contents of this Offer have been made except as are expressly set out herein or in the Lease. The Tenant acknowledges that no indemnities of the Landlord in favour of the Tenant have been given under this Offer and any indemnities of the Landlord in favour of the Tenant given under the Lease will not apply during the Extension of Term or be restated under the lease extension and amending agreement, such indemnities being deemed to have expired with the expiry of the initial Term of the Lease. Should the Premises or the Building be identified as having asbestos containing materials present which require abatement pursuant to applicable laws, the same will be conducted in accordance with the Building’s Asbestos Management Plan (“AMP”). If an AMP for the Building is required pursuant to applicable laws, a copy will be made available for the Tenant's inspection on request.
10.ACKNOWLEDGEMENT OF AUTHORITY: GWL Realty Advisors Inc. (“GWLRA”) has executed this

Page 3

Offer on behalf of the Landlord. The covenants and agreements hereunder are the obligations of the Landlord only and are not obligations personal to or enforceable against GWLRA.
11.SCHEDULES: Schedules A, B, C shall form a part of this Offer.
12.CONDITIONS: This Agreement shall be conditional in favour of the Landlord for a period of 10 business days following the date of acceptance hereof by all parties and the receipt of all required financial information, upon the Landlord:
(a)obtaining final approval of the terms and conditions of this Offer from the Landlord’s approval committee, in its sole, absolute and subjective discretion;
(b)reviewing and being satisfied with, in its sole, absolute and subjective discretion, the credit and financial information of the Tenant;
(c)obtaining any required approval from its lenders;
(d)obtaining satisfactory waivers from any tenant or other occupant of the Building with existing rights in respect of the Premises; and
(e)completion by the Tenant of the Landlord's Environmental Assessment Form and the Landlord being satisfied, in its sole, absolute and subjective discretion, that the Tenant's occupancy and use of the Premises shall not have any detrimental environmental impact on the Building.
These conditions are for the sole benefit of the Landlord and may be waived by the Landlord at any time provided that if the Landlord does not notify the Tenant of the waiver or satisfaction of the foregoing conditions within the stipulated period, this Offer shall be null and void and the Tenant shall surrender the Premises and deliver up vacant possession thereof to the Landlord in accordance with the terms of the Lease, the Landlord shall return any deposit monies delivered pursuant to this Offer and neither party will have any further liability to the other hereunder.
So that the Landlord may make an informed decision in respect of the condition set out under subparagraph (b) and (e), the Tenant shall submit, immediately upon acceptance hereof by the Tenant, all information required by the Landlord in order for the Landlord to make a proper assessment of the Tenant, including the information requested in the form(s) attached as Schedule B and Schedule C.
Tenant’s Conditions: This Agreement shall be conditional in favour of the Tenant for a period of 7 business days following the date of acceptance hereof upon the Tenant obtaining final approval in respect of the business and financial terms herein from the Tenant’s approval committee. This condition is for the sole benefit of the Tenant and may be waived by it at any time provided that if the Tenant does not notify the Landlord of the waiver or satisfaction of the foregoing condition within the stipulated period, this Agreement shall be null and void and neither party will have any further liability to the other hereunder.
13.NOTICES: All written communication to be given or made under this Offer shall be either personally delivered or sent by registered mail postage prepaid, except in cases of an actual or threatened postal disruption, as well as by electronic mail, to the parties at the addresses set out below. The time of giving such written communication shall be: (i) if delivered, when delivered in person, (ii) if mailed, on the 3rd business day after the date of mailing, and (iii) if sent by electronic mail, provided the email is received prior to 5:00 p.m. on a business day, the day upon which the email is sent, failing which, the next business day.
						
	Tenant:	MedAvail Technologies Inc.

Page 4

						
		c/o CBRE Limited
5935 Airport Road, Suite 700
Mississauga, ON
L4V 1W5
Attention: John Potter;
		
	Landlord:	c/o GWL Realty Advisors Inc.
1 City Centre Drive, Suite 300
Mississauga, ON L5B 1M2
Fax: 905-615-8128
Attention: Leasing Department.

All other communications shall be given or made in accordance with the Lease.
14.BROKERS: The parties acknowledge that: (a) CBRE Limited represents and owes a fiduciary duty to the Tenant in connection with this Offer but shall be compensated by the Landlord; (b) GWL Realty Advisors Inc. is a registered broker who represents and owes a fiduciary duty to the Landlord in connection with this Offer; and (c) the brokers have recommended that the parties obtain advice from their respective legal counsel prior to signing this Offer. The Landlord and the Tenant further acknowledge that the information provided by the brokers is not to be construed as expert legal or tax advice and the parties are cautioned not to rely on that information as such.
15.TIME OF ESSENCE: Time will be of the essence of this Offer.
16.CAPITALIZED TERMS: Unless specifically defined herein, all capitalized terms will have the meaning given to them in the Lease, as extended and amended by the lease extension and amending agreement.
17.CONFIDENTIALITY: The Tenant acknowledges that the contents of this Offer and all information obtained by Tenant in relation to the Premises, the Building, the Landlord or its manager, are strictly confidential, and the Tenant covenants not to disclose to any person, not allow disclosure of same, to any third party, except its professional advisors, in their capacity as such (in which case Tenant shall obtain a similar covenant of confidentiality from such advisors) or as may otherwise be required by law.
18.SEVERABILITY: Should any provision of this Offer be or become invalid, void, illegal or not enforceable, such provision shall be considered separate and severable from this Offer and the remaining provisions shall remain in force and be binding upon the parties hereto as though such provision had not been included.
19.TELECOMMUNICATIONS: The Tenant may, at its own expense, utilize a telephone or other telecommunications service provider of its choice, with the Landlord's prior written consent, which consent may not be unreasonably withheld, and provided the service provider executes the Landlord's standard form of license agreement (a copy of which is available upon request). All telecommunication cables and wiring installed in the Premises or Building by the Tenant (or on the Tenant's behalf) shall be properly tagged upon installation at both ends, including the Tenant's name and Unit/Suite number and, the Tenant shall, at its expense prior to the expiration of the Term, remove all telecommunication cables and wiring installed by the Tenant (or on the Tenant's behalf) in the Premises and Building.
20.MARKETING: Publication or use by the Landlord, or its representatives, of any photograph, print, video or film of the Building, Premises or Lands, for advertising or promotion of same, and which show the Tenant’s trade names, trademarks, logos or other identifying marks (the “Marks”), shall be deemed not to infringe any Tenant’s rights in respect of such Marks, and shall not require Tenant’s consent to use of the Marks nor entitle the Tenant to any compensation therefor.

Page 5

21.REDEVELOPMENT/DEMOLITION: As per the Existing Lease.
This Offer is open for acceptance by the Tenant until 5:00 p.m. on February 20th, 2019 after which it shall be null and void and of no further force or effect.
						
	Yours truly,	
		
	GWL REALTY ADVISORS INC.
as agent and on behalf of The Great-West Life Assurance Company and
801611 Ontario Limited
	
		
		
	/s/ Shannon King	
	Shannon King
Leasing Manager
Direct Dial: 905-361-2273	

Page 6

The foregoing is agreed and accepted this   21  day  of   February      , 2019  .
						
	TENANT:
MEDAVAIL TECHNOLOGIES INC.	
		
	Per:	/s/ LORI VALENTINI
	Name:	LORI VALENTINI
	Title:	VP FINANCE
		
	Per:	
	Name:	
	Title:	
	l/We have authority to bind the company.	

Subject to Section 12 hereof, the foregoing is agreed and accepted this  14  day of   March      , 2019   .
						
	LANDLORD:
THE GREAT-WEST LIFE ASSURANCE COMPANY AND
801611 ONTARIO LIMITED by their agent GWL Realty
Advisors lnc.	
		
	Per:	/s/ JONAS VARRIK
	Name:	JONAS VARRIK
	Title:	Director, Asset Management
		
	Per:	/s/ PHILIP GUNN
	Name:	PHILIP GUNN
	Title:	VICE PRESIDENT, ASSET MANAGEMENT
	We have authority to bind the company.	

Page 7

SCHEDULE A
LANDLORD’S WORK AND TENANT’S WORK
1.LANDLORD’S WORK
The Landlord is not required to do any work or provide any materials to or in respect of the Premises and the Tenant accepts the Premises in its “as-is, where-is” condition as of the Effective Date
Any costs to the Landlord resulting from the Tenant’s use or layout of, or alterations or changes to, the Premises shall be at the Tenant’s sole cost. All further renovations, alterations or improvements in or to the Premises are the sole responsibility of the Tenant and shall be undertaken and completed at the Tenant's expense and strictly in accordance with the provisions of the Lease and the Landlord's design criteria manual for the Building.
2.TENANT’S WORK
The Tenant will complete, at its sole cost, all work other than the Landlord's Work, if any, within the Premises. All Tenant’s Work prior to and following the Effective Date (the “Tenant’s Work") shall be completed in accordance with this Offer and the Lease and conducted as follows:
(i)In a good and workmanlike manner by contractors approved by the Landlord, acting reasonably, in advance;
(ii)In accordance with professionally prepared plans and specifications approved by the Landlord prior to the commencement of any of the Tenant’s Work and the Landlord’s Design Criteria Manual for the Building. It is understood and agreed that the Landlord may withhold or condition its consent in its sole discretion if any work to be performed by the Tenant may affect the exterior aesthetics, structure, or the electrical, mechanical, lighting, heating, ventilating, air-conditioning, sprinkler, fire protection or any life-safety systems of the Building, and any such work, if approved by the Landlord, shall be performed at the Tenant's cost, by contractors designated by the Landlord;
(iii)So as not to disturb or add to the Premises, Building or Lands any hazardous building materials, defined and regulated as Designated Substances under the Occupational Health and Safety Act, or any other hazardous substances designated as such under applicable legislation. Any Tenant’s Work that may impact friable or non-friable asbestos is to be handled in accordance with the procedures directed by the Landlord;
(iv)If the Landlord and Tenant are performing work within the Premises at the same time, the Tenant's contractors shall be subordinate to the Landlord's general contractor as required by applicable law and any additional associated cost to the Landlord shall be borne by the Tenant; and
(v)The Tenant shall be responsible for obtaining all necessary permits and licenses, including close-out documents, from governmental authorities with respect to the Tenant’s Work.
The Tenant shall pay: (A) all reasonable fees charged by the Landlord or its representatives or consultants in connection with (i) the Landlord's review of the Tenant's plans and specifications, and (ii) the Landlord's supervision of the Tenant's Work, and (B) all costs related to (i) building services provided during construction of the Tenant’s Work (including but not limited to elevator access, utility consumption and garbage removal) and (ii) loading the Tenant's “as-built” drawings into the Landlord's plan management database (the “Additional Charges”). If the Tenant elects to use the Landlord's project manager or construction manager (the “PM”) as its project manager for the Tenant’s Work, the Tenant shall pay, in addition to the Additional Charges, a co-ordination fee to the PM at a commercially competitive rate. The Tenant shall ensure that there are no liens registered or claimed with respect to any part of the Tenant's Work.
3.REPAYMENT OF ARREARS: The Tenant has failed to pay Base Rent and Additional Rent due under the Lease totalling $15,672.15 as of December 17th, 2018 (the "Arrears”) inclusive of applicable HST. The Arrears shall be repaid to the Landlord in 2 equal installments in the amount of $7,836.08 payable on or

Page 8

before April 30th, 2019 and the amount of $7,836.08 on or before August 31, 2019 (the "Repayment Amount"). The payments shall be made by certified cheque. If the Tenant is in default of any of its obligations under this Agreement or the Lease, the remainder of the Arrears and all other amounts payable under this Agreement and the Lease shall immediately become due and payable. The Tenant hereby waives, releases and surrenders all of its rights, claims and interest in and to any refunds or adjustment credits in respect of amounts paid or payable on account of Additional Rent under the Lease, to which it is now or may become entitled from time to time until such time as the whole of the amount payable under this Section and any and all other arrears of Additional Rent have been recovered by the Landlord.
The Landlord may, at its option, terminate this Agreement immediately in the event:
(i)the Tenant fails to pay any Repayment Amount, Base Rent, Additional Rent, or any other costs and expenses as and when required under this Agreement or the Lease, or if the Tenant defaults in the performance of any of its other obligations under this Agreement or the Lease;
(ii)the Tenant or any officer, director, principal shareholder, employee, agent, associate or affiliate of the Tenant makes any of the terms of this Agreement known to any other person, it being acknowledged by the Tenant that the terms of this Agreement and the concessions granted hereby to the Tenant are highly confidential; or
(iii)the Tenant becomes bankrupt or insolvent or takes the benefit of any act now or hereafter in force for bankrupt or insolvent debtors, or if the Tenant is a corporation and any order shall be made for the winding-up of the Tenant or other termination of the corporate existence of the Tenant, or if any other situations arise which have the effect of changing the business relationship between the Tenant and the Landlord.
In the event the Landlord elects to terminate this Agreement as provided in this Section, or upon the occurrence of the event of any monetary or other default by the Tenant under this Agreement or the Lease at any time during the Term, whether or not the Landlord elects to terminate the Agreement, the remainder of the Arrears plus applicable taxes and interest under the Lease shall immediately become due and payable in addition to any other rights and remedies available to the Landlord under the Lease or at law and the Landlord will be entitled to exercise all of its rights and remedies in respect of any amounts due in accordance with the terms of the Lease as they exist in the absence of this Agreement.
4.  OPTION TO EXTEND: Provided the Required Conditions have been met, the Tenant will have a non­transferable right to extend the Term for one (1) period of two (2) years, upon written notice given to the Landlord at least nine (9) months but not more than twelve (12) months prior to the expiry of the initial Term, failing which this option to extend and any subsequent option to extend shall be null and void. Upon exercising any option to extend, the Tenant shall have no further right to the extension option so exercised. Base Rent payable during the extension term shall be based upon the then-prevailing fair market net rental for similar premises similarly located,provided that in no event shall the annual Base Rent be less than the Base Rent payable by the Tenant on a per square foot basis in the last year of the initial then-current Term. If the parties cannot agree on the Base Rent payable during the extension term by no later than six 6 months prior to the expiry of the initial Term, the within option shall be null and void and of no effect.
5.  EXISTING LEASE:
All other terms and conditions of the Existing Lease, including any and all amendments, shall remain in full force and effect.
6.  LEGAL ADVICE:
The parties to this Agreement acknowledge that CBRE Limited has recommended that they obtain advice

Page 9

from their Legal Counsel prior to signing this document. The parties further acknowledge that no information provided by CBRE Limited is to be construed as expert legal or tax advice.
[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]

Page 10

SCHEDULE B
																																																									
		
										Request Form							
												Requested by:							
		1 City Centre Drive, Suite #300
Mississauga, Ontario L5B 1M2
Tel: (905) 275-6600 Fax: (905) 615-8128																	
																			
												Project:							
																			
																			
																			
		Corporation/Business Name:						MEDAVAIL TECHNOLOGIES INC											
																			
		Address:		6665 MILLCREEK DRIVE, UNIT 1															
																			
		City/Town:			MISSISSAUGA					Province:		Postal Code:		L5N 5M4	Tel:	905 812 -0023			
																			
		Is Company Incorporated or Limited? ☐ Yes ☐ No
									Date of Incorporation:			2012-07-27			Province:		
																			
		GST #:						PST #:			HST #:	801036088 2501			NAICS Code:				
																			
		Signing Authority for Lease:					LORI VALENTINI					Title:	VP FINANCE						
																			
		Email Address:				LVALENTINI@MEDAVAIL.COM													

																																																									
		Individual:																	
		Adress:														Tel:			
		City/Town:								Province:			Postal Code:			Do you own? ☐ Yes ☐ No			
		Date of Birth:								SIN:			Drivers Licence #:						
																			
						MM	DD	YY											

																																																																					
	*	Bank:											Bank:										
		☐ Personal Account
							☑ Business Account
				☐ Personal Account
							☐ Business Account
			
		Address:											Address:										
		Transit #:						Account #:					Transit #:						Account #:				
		Account Manager:											Account Manager:										
																							
																							
		Landlord:											Can we contact Landlord? ☐ Yes ☐ No
										
		Address:																		Tel:			
																							
	*	Credit/Supplier:											Credit/Supplier:										
		Address:											Address:										
		Tel:						Contact:					Tel:						Contact:				
																							
	*	Credit/Supplier:											Credit/Supplier:										
		Address:											Address:										
		Tel:						Contact:					Tel:						Contact:				
																							
																							
		I/We understand that this information and form is given to assist you in analyzing our situation and to help you ascertain the possibility of such an agreement. The undersigned hereby declares that the above statements are true in substance and in fact. In connection with my/our application for credit, I/we hereby take notice that the services of credit reporting agencies will be obtaining bank reference information, including account balances and other credit information on behalf of GWL Realty Advisers Inc. and may be referring to a consumer report respecting me/us containing personal information and/or credit information and I/we hereby consent, thereto and to the disclosure of such information to other credit grantors or consumer reporting agency. And furthermore, I/we are agreeable to the Landlord obtaining subsequent credit information throughout the duration of the Lease.																					
		Date:		Feb 20, 2019																			
																							
		Name (print):				LORI VALENTINI							Signature:				/s/ LORI VALENTINI						

*SEE ATTACHED CREDIT APP

Page 11

SCHEDULE C
ENVIRONMENTAL ASSESSMENT FORM
						
	Tenant Name:	MEDAVAIL TECHNOLOGIES INC
		
	Tenant Representative:	GEORGE BURROWS
		
	Leasing Agent:	JOHN POTTER
		
	Leasing Identification Number:	
		
	Date of Completion: (yyyy/mm/dd)	2019/02/20

																		
	1.	Has the proposed tenant ever previously occupied a building owned by this owner?		Yes
		No

						
						ü
						
	2.	Does the proposed tenant's business involve the use, storage and/or resale of any hazardous materials?		Yes
		No

						
						ü
						
	3.	Will the proposed tenant's business use process equipment requiring permits or certificates of approval to operate (such as exhaust equipment, waste water treatment equipment, petroleum storage tanks)?		Yes
		No

						
						ü
						
	4.	Can the proposed tenant's business be classified as any of or similar to the following:		Yes		No

						
		4.1	Retail fuel station?			ü
						
		4.2	Automotive or truck repair facility?			ü
						
		4.3	Commercial printing or painting?			ü
						
		4.4	Solvent based dry cleaning?			ü
						
		4.5	Photo developing laboratory?			ü
						
		4.6	Junkyard/landfill?			ü
						
		4.7	Waste processing or recycling facility?			ü
						
		4.8	Waste treatment, storage or disposal operation?			ü
						
		4.9	Medical or dental facility?			ü
						
	5.	Will the proposed tenant's business require them to install aboveground or underground storage tanks (Chemical or Petroleum) on the property or in their tenant space?		Yes		No

						
						ü
						
	6.	Will the proposed tenant's business require them to install any sumps, pits, floor trenches, oil/water separators, or other subsurface facilities?		Yes
		No

						
						ü
						
	7.	Will the proposed tenant's business operations require them to have emergency response procedures related to spills, incidents, exposures, or other releases of chemicals?		Yes
		No

						
						ü
						

Page 12

																																				
	8.	Will the proposed tenant's business use, store, sell or manufacture any hazardous materials controlled under the Workplace Hazardous Materials Information System (WHMIS) regulations such as:								Yes
		No

												
												
		8.1	Flammable/Combustible Materials (such as gasoline, propane)?									ü
												
		8.2	Compressed Gases (such as oxygen, acetylene)?									ü
												
		8.3	Dangerously Reactive Materials (such as butadiene, sodium cyanide)?									ü
												
		8.4	Oxidizing Materials (such as nitrates, inorganic pesticides)?									ü
												
		8.5	Poisonous Substances (such as acids, caustics, gasoline)?									ü
												
		8.6	Toxic Materials (such as lead, benzene)?									ü
												
		8.7	Corrosive Substance (such as battery acids, caustic cleaners)?									ü
												
		8.8	Biohazardous Materials (such as contaminated blood, medical waste, sharps (needles))?									ü
												
	9.	Will the proposed tenant's business generate any hazardous waste (solid, liquid, or gas) that will require special disposal?								Yes
		No

												
												ü
												
	10.	Will the proposed tenant be bringing any equipment onto the property that contains hazardous material such as:								Yes
		No

												
		10.1	PCBs (old transformers, capacitors, or switching gear)?									ü
												
		10.2	Ozone depleting substances (air conditioners, coolers, refrigerators, halon fire extinguishers, etc)?									ü
												
		10.3	Asbestos?									ü
												
		10.4	Lead?									ü
												
		10.5	Other Designated Substances?									ü
												
	11.	Will the proposed tenant's business use, sell, or manufacture pesticides?								Yes
		No
												
												ü
												
	NOTES:											
												
												
												
	Date this			20		Day of		FEBRUARY		20		19.
												
		LORI VALENTINI, VP FINANCE										
	And	MEDAVAIL TECHNOLOGIES INC.										
												
		/s/ LORI VALENTINI										
		I/We have authority to bind the CorporationDocument

Exhibit 10.23
									
		Notice: certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.	1 of 28

FOIA NOTICE: This document contains Express Scripts, Inc. proprietary information and/or data. Recipient, by accepting this document, agrees that it will not duplicate, use, or disclose-in whole or in part-this document, or the information contained therein, or any part thereof to others for any other purpose except as specifically authorized in writing by Express Scripts, Inc. EXEMPT FROM PUBLIC DISCLOSURE: Information contained herein is confidential information of Express Scripts, Inc. and is exempt from public disclosure under 5 U.S.C. §552(b). Do not disclose outside of the recipient organization of the United States Government.
NO ALTERATIONS TO THIS DOCUMENT SHALL BE BINDING UNLESS INITIALED BY DULY AUTHORIZED REPRESENTATIVES OF PROVIDER AND ESI.
EXPRESS SCRIPTS, INC. PHARMACY PROVIDER AGREEMENT
THIS EXPRESS SCRIPTS, INC. PHARMACY PROVIDER AGREEMENT (the “Agreement”) is made and entered into as of the Effective Date (as defined in Section 1.2), by and between Express Scripts, Inc., a Delaware corporation, on behalf of itself and Medco Health Solutions, Inc. (together, “ESI”) and MedAvail Pharmacy INC. dba APM Pharmacy, NCPDP# 0361725, a corporation organized under the laws of the state of Arizona (the “Provider”). As required by the New York State Department of Health, solely with respect to services rendered in the state of New York under this Agreement to any Member of any Prescription Drug Program offered by a Sponsor, as such capitalized terms are herein defined, which is certified as a managed care organization under Article 44 of the New York State Public Health Law, Diversified NY, IPA, Inc. ("IPA"), a corporation and wholly-owned subsidiary of Express Scripts, Inc. (together with IPA, "ESI"), shall be a party to this Agreement.
RECITALS
WHEREAS, ESI administers and manages Prescription Drug Programs for its Sponsors (as defined in Sections 1.5 and 1.9 of this Agreement, respectively), which programs include claims administration, mail service dispensing and other pharmacy benefit management services; and
WHEREAS, in order to fulfill its service obligation to its Sponsors, ESI maintains a variety of pharmacy networks; and
WHEREAS, Provider desires to participate in one or more of ESI’s pharmacy networks to provide pharmacy services to eligible Members (as defined in Section 1.3), all in accordance with and subject to the terms and conditions set forth in this Agreement and the Provider Manual.
NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ESI and Provider hereby agree as follows:
TERMS AND CONDITIONS
1.DEFINITIONS. As used in this Agreement, and as set forth in the Provider Manual, each of the following terms (and the plural thereof, when appropriate) shall have the meaning set forth herein, except where the context makes it clear that such meaning is not intended:
1.1“Affiliate” means, as to either party: (a) any division of a party other than the division(s) with direct responsibility for carrying out the party’s obligations under this Agreement, and (b) any corporation or other entity which, directly or indirectly, through one or more intermediaries, controls (i.e., possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract, or otherwise), is controlled by, or is under common control with such party.
1.2“Effective Date” shall mean the date upon which ESI executes this Agreement as set forth on the signature page of this Agreement.
1.3“Member(s)” means a subscriber and his or her eligible dependents to which benefits are available pursuant to a Prescription Drug Program.
1.4“Pharmacy” or “Pharmacies” means the pharmacy or pharmacies listed on Exhibit B, attached hereto and incorporated herein by this reference, which are owned or operated by Provider, licensed by the appropriate state board of pharmacy and other applicable regulatory authorities, meets the definition of Retail Provider (as 
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			2 of 28

defined in Section 1.8) and has been approved by ESI to provide services hereunder. For the purposes of this Agreement, "Pharmacy" or "Pharmacies" shall include any stand-alone, self-contained machine(s), apparatus(es), booth(s), stand(s), or such other similar structure(s) owned or operated by Provider and used for the purpose of dispensing Covered Medication(s) to member(s) ("Pharmacy Kiosk(s)"). If Provider owns or controls more than one Pharmacy, then Provider shall cause all such Pharmacy(ies) to provide services to Members in accordance with this Agreement and to be bound by and comply with all of the provisions set forth herein and in the Provider Manual. “Provider" and “Pharmacy” are used interchangeably in this Agreement.
1.5“Prescription Drug Program” means any group or individual plan, policy, agreement or other arrangement sponsored, issued, or administered by a Sponsor, which includes pharmacy services or benefits related to utilization of pharmaceutical products and any Formulary. Sponsor may amend its Prescription Drug Program at any time, in its sole discretion, and such amendment shall not require the consent of Provider.
1.6“Provider Certification” shall mean the information form completed by Provider (and each of its Pharmacies) prior to the Effective Date of this Agreement and updated by Provider (and its Pharmacies, as applicable) as information therein changes as more specifically described in Section 2.2.b.
1.7“Provider Manual” shall mean the written handbook describing the practices, rules, operational requirements and policies and procedures established by ESI for Provider (and its Pharmacies) regarding their provision of Covered Medications to Members. It shall be the Provider’s responsibility to check for any updates to the Provider Manual. The Provider Manual may be revised from time to time by ESI in its sole discretion. Provider's failure to comply with any of the provisions of the Provider Manual shall be considered a breach of this Agreement. ESI’s Provider Manual may be obtained at: http://www.express-scripts.com/services/pharmacists/.
1.8“Retail Provider” shall mean a pharmacy that primarily fills and sells prescriptions via a Pharmacy Kiosk or a retail, storefront location, is determined by ESI to fulfill an ESI business need with respect to participation in its retail network(s), and meets such other criteria established by ESI from time to time including any specific needs of a population, as determined by ESI in its sole discretion. “Retail Provider” shall not include mail order, specialty, home infusion, dispensing physician, or Internet pharmacies or such other provider types that do not meet ESI’s Retail Provider criteria established from time to time.
1.9“Sponsor” means any contracted client of ESI related to a Prescription Drug Program.
2.SERVICES AND OBLIGATIONS OF PROVIDER.
2.1Verification of Eligibility. Provider shall verify the eligibility of Members utilizing ESI’s current online system or other method(s) approved by ESI and set forth in the Provider Manual. ESI shall have the right to reverse any claim submitted by Provider and offset such amount owed against any amount owing to Provider by ESI for any claim improperly submitted by Provider wherein Provider failed to correctly check an individual’s eligibility or verify that the prescription was issued in accordance with applicable laws, rules and regulations.
2.2Dispensing; Standard of Services; Credentialing and Recredentialing.
2.2.aGenerally. In addition to the provisions of Section 2.7 of the Agreement, Provider shall provide services hereunder, including the dispensing of Covered Medications: (i) under the supervision of a licensed pharmacist; (ii) in accordance with all applicable laws, rules and regulations; (iii) in accordance with the applicable Prescription Drug Program; (iv) in accordance with ESI’s online messaging that such Provider or Pharmacy receives from ESI; (v) in accordance with this Agreement, ESI’s current policies and procedures, the Provider Manual, and any quality assurance program(s); (vi) the design and Formulary applicable to the specific Prescription Drug Program; (vii) in accordance with the professional standards prevailing in the community at the time such services are rendered; and (viii) not engaging in any conduct that would jeopardize the health, welfare or safety of any Member.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			3 of 28

2.2.bCredentialing and Recredentialing.
2.2.b.1Generally. Provider and its Pharmacies shall be eligible to provide services hereunder, including dispensing Covered Medications, only upon satisfaction of any credentialing/recredentialing and additional requirements imposed by ESI, including, subject to subsection 2.2.b.3, the provision of timely written notice with any updates to the Provider Certification, as further described in the Provider Manual.
2.2.b.2Credentialing. The Provider set forth in the opening paragraph of this Agreement shall be eligible to provide services hereunder, including dispensing Covered Medications, only upon satisfaction of any credentialing/recredentialing and additional requirements imposed by ESI, including the provision of timely written notice with any updates to the Provider Certification set forth in Exhibit C. Failure to provide timely updated information to the Provider Certification or to comply with any other credentialing/recredentialing requirements required by ESI from time to time shall constitute a breach of this Agreement and ESI may terminate Provider in accordance with the provisions of Section 4.2.b or 4.2.c of this Agreement, in ESI's sole discretion.
2.2.b.3Delegation. Upon satisfaction of the Credentialing requirements set forth in Section 2.2.b.2, for each additional Pharmacy added under this Agreement, Provider shall complete, or cause a representative of each Pharmacy to complete and return to Provider, who will on a timely basis return to ESI, all credentialing and recredentialing materials required by ESI from time to time, including the Provider Certification set forth in Exhibit C, attached hereto and incorporated herein by this reference. In lieu of Provider completing, or causing each Pharmacy to complete and return the Provider Certification, Provider may, at its option, represent and warrant to ESI that it collects and maintains in its own format, on behalf of its Pharmacies, all of the information required by the Provider Certification by completing Exhibit D, “Provider Credentialing Representations and Warranties,” attached hereto and incorporated herein by this reference, on a timely basis. Notwithstanding any of the foregoing, Provider shall maintain such credentialing/recredentialing information in a readily retrievable format. Subject to all other conditions of acceptance, the parties acknowledge and agree that no Pharmacy shall be able to participate in any ESI network until such Provider Certification form or Exhibit D, as applicable, is received, accepted and approved by ESI. Provider shall be required to obtain up-to-date information on each Pharmacy and must update the Provider Certification annually either by: (i) requesting that each Pharmacy complete a new Provider Certification and remit the same to Provider, who will forward the same to ESI; or (ii) Provider re-executing the Provider Credentialing Representations and Warranties form set forth in Exhibit D and providing the same to ESI. Notwithstanding the immediately preceding sentence, in the event there is any change to the information contained in the Provider Certification relating to Provider or any Pharmacy, Provider shall provide timely written notice of such change(s) to ESI. An executed Exhibit D shall be the parties’ written agreement for the Provider to collect and maintain the information contained in the Provider Certification for each Pharmacy. In the event the Provider is responsible for maintaining credentialing and recredentialing information, including the Provider Certifications or the information contained therein, Provider acknowledges and agrees to provide a copy of the same to ESI within two (2) days of any request made by ESI.
2.2.b.4New Pharmacy Locations Added. Notwithstanding the foregoing, as new Pharmacies are added to Provider (vis-à-vis, an updated Exhibit B), the parties acknowledge and agree that a Pharmacy shall not be considered participating under this Agreement until ESI has received written notice in substantially the same form as the notice set forth in Exhibit E, attached hereto and incorporated herein by this reference, from the Provider that a new Pharmacy has been added, it has received the Pharmacy’s Provider 
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			4 of 28

Certification (or the equivalent information) and the representations and warranties in Exhibit D are applicable to such new Pharmacy and ESI has accepted and approved such Pharmacy for participation.
2.2.b.5Failure to Comply. Failure to provide timely updated information to the Provider Certification or to comply with any other credentialing/recredentialing requirements required by ESI from time to time shall constitute a breach of this Agreement and ESI may terminate Provider or any Pharmacy in accordance with the provisions of Section 4.2.b or 4.2.c of this Agreement, in ESI’s sole discretion. For purposes of this Section 2.2.b, “timely” shall mean within ten (10) days of the request for recredentialing or any change in information.
2.3Claims Submission and Processing.
2.3.aSubmission. Claims shall be submitted for eligible Members only. Provider shall submit each prescription drug claim to ESI in the most current NCPDP format for processing and payment as set forth in this Agreement and in the Provider Manual.
2.3.bTiming Requirements. Unless otherwise required by applicable law, all electronic claims for prescription drugs must be submitted to ESI within ninety (90) days after the prescription is filled, unless a longer period is allowed by Sponsor (the “Sponsor’s Timing"), then in such case, in accordance with the Sponsor’s Timing. Provider shall not receive payment for electronic claims submitted after such 90-day period or when applicable, after the Sponsor’s Timing. In the event Provider is instructed by ESI to file a paper claim for any reason, such paper claim shall be submitted in accordance with any instructions received from ESI and the guidance set forth in the Provider Manual.
2.3.cReversals for Failure to Pick-Up. Unless a shorter time period is required by a Sponsor or any law, rule or regulation (and then in accordance with such Sponsor’s requirements or law, rule or regulation), any prescription drug claims, for which prescription drugs were approved for payment by ESI and not picked up by the Member, in whole or in part, must be reversed online within thirteen (13) days of submission of the claim by the Pharmacy.
2.4Collection of Copayments; Member Hold-Harmless; Violation.
2.4.aCopayments. Provider shall collect from Members the lesser of the Usual and Customary Retail Price amount or the applicable Copayment indicated by ESI, or when applicable, the full Copayment when indicated by ESI, through its online processing system or if online processing is unavailable, in accordance with the Provider Manual. Copayments may not be waived or discounted and, unless directed by ESI in writing, Provider shall not collect any greater amount or any other taxes, fees, surcharges or compensation from any Member for any Covered Medications or services provided in connection therewith. In no event will ESI be liable for any Copayment.
2.4.bMember/Sponsor Hold Harmless. Except with respect to Copayments, Provider shall look solely to ESI for payment for Covered Medications and other covered services provided to Members pursuant to this Agreement, as further set forth in the Provider Manual.
2.5Coupons. Provider acknowledges that it is the Member’s or Provider’s responsibility to obtain reimbursement from the responsible party for the amount of any coupon accepted by Provider for a Covered Medication. Provider shall: (a) accurately apply all coupons to a Member’s claim, including the Copayment, if applicable; and (b) not seek additional reimbursement from Sponsor or any other insurer when such reimbursement would result in Provider being paid more than its contracted rate hereunder.
2.6Non-Discrimination. Provider shall not refuse to provide services required under any Prescription Drug Program or attempt to disenroll any Member, as further described in the Provider Manual.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			5 of 28

2.7Compliance with Agreement; Laws; Licenses and Permits. Provider shall, and shall cause its personnel to, be bound by and comply with the provisions of this Agreement and all applicable laws, rules and regulations including, but not limited to, fraud, waste and abuse laws and applicable state boards of pharmacy’s, other applicable governmental bodies’ laws, rules and regulations, and all required federal, state and local licenses, certificates and permits that are necessary to allow the Provider, the Pharmacy and pharmacist (as applicable) to dispense Covered Medications to Members, and any other certificates or qualifications that may be required by ESI from time to time. Provider shall notify ESI in writing immediately: (i) in the event any individual or vendor providing services, supplies, or medications to Provider is or has been excluded from participation in any Federal or state health care program or government contract, or is otherwise subject to any restriction by the Office of the Inspector General or other state or government agency; and (ii) in the event of any suspension, revocation, restriction, limitation or any other disciplinary action taken against or placed on any such license, certificate or permit or any suspension, restriction, limitation or exclusion from participation in any federal or state health care or other government program. In addition, Provider shall (and shall cause its pharmacists to) provide evidence of such good standing, certification and licensure without charge to ESI, a Sponsor or a designee of ESI or Sponsor within five (5) days of written request by ESI.
2.8Compliance with ESI’s Quality Assurance Programs (e.g., UR, QA, etc.), Formularies, Sponsor's Prescription Drug Program Requirements and Provider Manual. Provider shall cooperate with ESI and participate in any and all utilization review, quality assurance programs, procedures, peer review, credentialing/recredentialing processes, audit systems, each Sponsor's Prescription Drug Program requirements and any complaint resolution procedures established by ESI or required by a Sponsor from time to time. Without limiting the generality of the foregoing, Provider shall: (a) cooperate with ESI’s procedures for utilization review and generic substitution, as set forth from time to time in the Provider Manual; (b) comply with ESI’s procedures for calling prescribers to facilitate generic substitution and Formulary compliance, and other programs established by a Sponsor, as set forth from time to time in the Provider Manual; and (c) comply with the Provider Manual.
2.9Hours of Service. Provider shall provide services hereunder according to the hours of service set forth in Provider’s credentialing/recredentialing information and any additional hour requirements established by ESI from time to time.
2.10No Circumvention of Usual and Customary Retail Price. Provider shall provide ESI with prompt written notice of any changes to Provider’s locations set forth in Exhibit B, including, additions and deletions, so that ESI may update its records. Provider shall not undermine Usual and Customary Retail Price or compound pricing in any way, including, but not limited to: (a) owning, operating or affiliating with a non-participating Provider; or (b) separating cash and third-party prescription business. Provider shall not participate in any ESI network if ESI determines in its sole discretion that Provider has taken actions to undermine Usual and Customary Retail Price and/or compound pricing. Additionally, any right ESI has to offset amounts owing to ESI hereunder against amounts owed to Provider or any Pharmacy may, at ESI’s sole discretion, be offset against amounts owed to Provider or any Pharmacy regardless of which location is responsible for the amount owed.
2.11Records. Provider shall, and shall cause its Pharmacies to, for a period of five (5) years following the Agreement year in which Covered Medications were provided to Members, or, if longer in accordance with applicable law, maintain: (i) all medical, business, financial and administrative records, including, all books, contracts, medical records, and patient care documentation; (ii) original prescriptions; (iii) signature logs (or other evidence approved in writing by ESI); (iv) wholesaler, manufacturer and distributor purchase records; (v) prescriber information; (vi) patient profiles; and (vii) such other records and information relating to Covered Medications provided to Members as may be required by ESI from time to time, as further set forth in the Provider Manual.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			6 of 28

2.12Audit.
2.12.aGenerally. Provider agrees that ESI or a third party authorized by ESI may, upon request, inspect, review, audit and reproduce, during Provider’s regular business hours and without charge to ESI, any of Provider’s medical, business, financial, and administrative records, including prescription records, all books, contracts, medical records, and patient care documentation; original prescriptions; signature logs (or other evidence allowed by ESI as set forth in the Provider Manual); wholesaler, manufacturer and distributor purchase records; prescriber information; patient profiles; and such other records and information relating to Covered Medications provided to Members or performance under this Agreement, as may be required by ESI from time to time as further described in the Provider Manual.
2.12.bAudit Appeals. The obligations of the Provider and the procedure and guidelines for appealing audit results shall be as set forth in the Provider Manual.
2.13Disaster Planning. Provider agrees that it shall cooperate and coordinate with ESI in implementing any disaster planning efforts undertaken by ESI to ensure that Members receive continuous care, including continued provision of prescription medications together with Covered Medications to Members, in the event of any Force Majeure (as described in Section 7.6 of this Agreement).
2.14Counterfeit Reporting. Provider agrees that it shall cooperate and coordinate with ESI in implementing any counterfeit identification, investigation, tracking and reporting efforts undertaken by ESI. Provider must notify ESI in writing if it becomes aware that any counterfeit drugs have been provided to Members by Provider. Further, Provider represents and warrants (for itself and on behalf of its Pharmacies) that it (and its Pharmacies) purchases prescription drugs and supplies only from reputable wholesalers and/or manufacturers in accordance with the prevailing industry standards.
2.15Pharmacy Kiosks. Provider agrees to be solely responsible and liable for the maintenance, operation, and dispensing from any Pharmacy Kiosks and hereby represents and warrants that any such Pharmacy Kiosks: (i) comply with all applicable laws, rules and regulations including, but not limited to, the Prescription Drug Marketing Act ("PDMA"); and (ii) are (as applicable) appropriately licensed by the appropriate state board(s) of pharmacy or medical practice act (or, for non-physician health care professionals with the authority to prescribe and dispense prescription medications, such professional's applicable practice act). Provider further acknowledges and agrees that Provider's maintenance and use of and dispenses to Members from Pharmacy Kiosks shall, in all respects, be subject to the terms and conditions of this Agreement including, but not limited to, any exhibits, appendices, Provider Certification, Provider Manual, and any requirements of a Sponsor's Prescription Drug Program. ESI may exercise any rights under this Agreement as it relates to any Pharmacy Kiosk to the same extent ESI would be permitted to do so with respect to Provider and any Pharmacy.
3.PAYMENT FOR COVERED MEDICATIONS; PROVIDER CHARGES; INCORRECT PAYMENTS.
3.1Generally.
3.1.aPayment for Covered Medications. For services performed in accordance with the terms and conditions of this Agreement, ESI shall pay Provider the rates as set forth in the applicable rate sheet(s), attached hereto and incorporated herein by this reference, less the applicable Copayment. Except for Copayments, Provider shall look solely to ESI for payment for Covered Medications and other covered services provided to Members pursuant to this Agreement and not to Sponsor. Approved claims for Covered Medications shall be paid in accordance with federal or state law and the Provider Manual. Additional information or rejected or disputed claims must be submitted or resubmitted, as applicable, by Provider within thirty (30) days of the request for additional information, initial rejection or dispute. ESI may deny payment for any claim not submitted within this time period. Further, ESI may refuse to pay any claim or may reverse payment of any claim that is not submitted in accordance with the terms and conditions of this Agreement.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			7 of 28

3.1.bProvider Charges. Provider (or its Pharmacy(ies), as the case may be) shall be solely responsible for expenses, costs, charges and fees relating to transmitting claims or other online activities or information to ESI or its designee. Further, for every transaction a Provider (or its Pharmacy(ies)) transmits to ESI, ESI shall charge such Provider a service fee of up to an average of [***] per transaction. Such service fee shall be immediately due and owing to ESI and ESI shall have the right to deduct such outstanding transaction fees from any amounts payable to Provider. For purposes of this Agreement, “transaction” shall mean each payable claim for reimbursement to Provider for a current Member for Covered Medications.
3.2Incorrect Payments.
3.2.aGenerally. Any payments made to Provider (or any Pharmacy) in excess of any amount properly determined to be due by ESI may be recovered by ESI from Provider (or any individual Pharmacy). ESI shall notify the Provider (and Pharmacy, if applicable) in writing of such excess payment(s) and shall have the right to either offset the excess payment amount as provided in Section 2.12 (audit) or require immediate reimbursement from Provider. In the event any such excess payment constitutes a material excess payment and upon Provider’s request, ESI shall work with Provider on a reasonable repayment schedule. For the purposes of this agreement, a material excess payment shall be an amount of one hundred thousand dollars ($100,000) or more.
3.2.bRemittance Advices. Provider acknowledges and agrees that it is obligated to review remittance advices received from ESI to verify their accuracy. Provider must notify ESI in writing of any alleged error, miscalculation, or discrepancy (and a detailed basis of such allegation) whether paid, denied, rejected or reversed, within sixty (60) days of the date of each remittance advice if it disputes any information thereon as further described in the Provider Manual. Otherwise, Provider will be deemed to have confirmed the accuracy of the claims processed under such remittance advice and waives any claim it may have for errors, miscalculations or discrepancies if it fails to object within such 30-day period. If Provider does not notify ESI in the manner and time provided herein, then, neither shall ESI have any further responsibility, nor shall Sponsor have any responsibility, with respect to such remittance. Notwithstanding any of the foregoing, in no event shall ESI be responsible for remittance amounts above or beyond the appropriately applied rates, as determined by ESI, that are agreed to by the parties as set forth in the applicable rate sheet.
4.TERM AND TERMINATION.
4.1Term. Unless earlier terminated as provided in Section 4.2 of this Agreement, the term of this Agreement shall begin on the Effective Date and continue for a period of three (3) years (the “Initial Term”). Thereafter, this Agreement shall automatically renew for successive one (1) year terms (each, a “Renewal Term”) unless (i) a party gives at least ninety (90) days prior written notice to the other of such party’s intent not to renew this Agreement or (ii) it is earlier terminated as provided in Section 4.2 (the “Initial Term” and any “Renewal Term” shall collectively be referred to herein as the “Term”).
4.2Termination.
4.2.aWithout Cause. This Agreement may be terminated by ESI without cause upon at least ninety (90) days written notice to Provider (or such longer period as may be required by law), with such termination effective at the end of such notice period.
4.2.bBreach. In the event a party defaults in the performance of any of its obligations under this Agreement (the “Defaulting Party”), the other party (the “Non-Defaulting Party”) may give written notice to the Defaulting Party of such breach. If the Defaulting Party has not cured such breach to the reasonable satisfaction of the Non-Defaulting Party within thirty (30) days after it receives such notice, then the Non-Defaulting Party shall have the right to immediately terminate the Agreement as of the expiration of the 30-day cure period. In addition to ail other rights, ESI shall have the right to: (i) suspend any and all obligations of ESI hereunder and in connection with this Agreement; (ii) impose investigation and handling fees as further described in the Provider Manual; and/or (iii) 
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			8 of 28

offset against any amounts owed to Provider under this Agreement or under any other agreement between ESI and Provider, which are owing or required to be paid by Provider to ESI. These rights and remedies are in addition to any and all other rights that exist or are available or may exist or be available to ESI pursuant to this Agreement, at law or in equity.
4.2.cImmediate Termination. Notwithstanding the provisions contained in Section 4.2.b, ESI shall have the right to immediately terminate this Agreement upon written notice to Provider in the event that: (i) Provider ceases to be licensed by the appropriate licensing authority; (ii) Provider submits a fraudulent prescription drug claim or any information in support thereof; (iii) Provider is insolvent, goes into receivership or bankruptcy or any other action is taken on behalf of its creditors; (iv) Provider fails to comply with the claims submission and processing requirements as set forth in Section 2.3 or fails to comply with Section 2.4 of this Agreement or any of ESI’s policies and procedures including, but not limited to, the Provider Manual and/or quality assurance and/or utilization review procedures; (v) no longer meets credentialing requirements; (vi) ESI determines that the Provider is dispensing Covered Medications in violation of any applicable law, rule and/or regulation; (vii) Provider is excluded from participating in any federal or state health care program; (viii) Provider fails to maintain insurance as required by Section 6.1 of this Agreement; (ix) Provider has not submitted a claim to ESI for ninety (90) calendar days; (x) Provider (or any Pharmacy) fails to comply with any audit or investigative request, including the provision of information, made by ESI or any Sponsor or their designee, within the time period stated in such request; (xi) a determination is made by ESI that Provider (or any Pharmacy) failed to document purchases of prescriptions drugs sufficient to support its claims for reimbursement to ESI; or (xii) ESI determines that Provider’s continued performance of services poses a risk to the health, welfare or safety of any Member.
4.2.dSponsor Prescription Drug Programs. Provider acknowledges and agrees that Sponsors may not utilize Provider and/or all or any Pharmacies in a network for their respective Prescription Drug Programs. Accordingly, without terminating this entire Agreement, ESI may terminate Provider (or any Pharmacy) from participating in any Sponsor’s Prescription Drug Program in accordance with Sponsor's timing.
4.2.eSpecific Pharmacies. ESI may terminate any Pharmacy’s participation under this Agreement in accordance with Section 4.2 subsections (a) through (d), without terminating Provider or the entire Agreement.
4.2.fNetwork Termination. With respect to Provider’s participation in any network (as evidenced by an executed rate exhibit), Provider’s or any Pharmacy’s participation in a specific network (and therefore, the specific rate sheet) may be terminated by ESI pursuant to and in accordance with Section 4.2 subsections (a) through (d) without terminating the entire Agreement or Provider's or a Pharmacy’s participation in any other network.
4.2.gClosure of Networks. Notwithstanding any notice requirements of Section 4.2, in the event an ESI client ceases to utilize ESI, a client-specific network is terminated or ESI terminates (ceases operation of) an entire network, the notice requirement to Provider will be waived.
4.2.hEffect of Termination.
4.2.h.1In the event of termination of this Agreement or any rate sheet for any reason, in addition to all other rights and remedies ESI may have under this Agreement, at law or in equity, ESI shall have the right to offset from any amounts owing to Provider any amounts which Provider may owe to ESI.
4.2.h.2Upon the expiration or termination of this Agreement or any rate sheet, for any reason or no reason, this Agreement will remain in effect for purposes of those obligations and rights arising prior to the effective date of such expiration or termination. In addition, upon expiration or termination of this Agreement or any rate sheet for any reason or no reason 
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			9 of 28

(with the exception of Immediate Termination pursuant to Section 4.2.c), and upon ESI's request, Provider shall (i) continue to provide Covered Medications to Members during the longer of a one hundred and twenty (120) day period following the date of such termination or expiration or such other period as may be required by federal or state laws, regulations, standards or requirements applicable to a Sponsor (the "Continuation Period"), and, if further requested by ESI, Provider shall (ii) continue to assist in the transition of Members to another provider, (iii) continue to comply with and abide by all the terms and conditions of this Agreement including any applicable rate sheet, and (iv) sign any extensions to this Agreement necessary in order to allow ESI, Sponsor, and/or Provider to comply with all applicable laws, rules and regulations. During the Continuation Period, Provider will be compensated in accordance with the current Agreement, including any applicable rate sheet that existed just prior to expiration or termination of this Agreement or the applicable rate sheet and shall accept such compensation as payment in full.
4.2.iNotice. In the event of termination of this Agreement or any rate sheet for any reason, ESI may notify Sponsors and their Members regarding such termination.
5.CONFIDENTIALITY.
5.1Generally. Provider acknowledges and agrees that in the performance of services hereunder, Provider will comply with the Confidentiality provisions set forth in the Provider Manual and as set forth in this Agreement.
5.2Exceptions. The term “Confidential Information” shall not include: (a) information which is public or becomes public through no fault of the party having the obligation to keep such information confidential (the “Receiving Party”); (b) information which the Receiving Party has knowledge of prior to receipt hereunder, other than under an obligation of confidentiality, as evidenced in writing and dated prior to the Effective Date of this Agreement; and (c) information which is received by the Receiving Party from a third person not under an obligation of confidentiality.
5.3HIPAA. ESI shall and Provider shall comply with all federal and state laws, rules, and regulations regarding the confidentiality of patient information, including, but not limited to, compliance with the Health Insurance Portability and Accountability Act of 1996, as amended (“HIPAA”), and the Health Information Technology for Economic and Clinical Health Act, as amended ("HITECH Act"), including all applicable rules, regulations, and official guidance promulgated in connection with HIPAA and the HITECH Act, by the U.S. Department of Health and Human Services or otherwise.
5.4Remedies. Provider acknowledges and agrees that any breach of Section 5 of this Agreement would cause ESI immediate and irreparable injury or loss that cannot be fully remedied by monetary damages. Accordingly, if Provider fails to abide by the terms and conditions set forth in Section 5 of this Agreement, ESI shall be entitled to specific performance, including immediate issuance of a temporary restraining order or preliminary injunction enforcing the terms of this Agreement, and to judgment for damages (including reasonable attorneys’ fees and costs) caused by the breach, and to all other legal and equitable remedies available to ESI.
6.LIABILITY INSURANCE; INDEMNIFICATION AND LIABILITY.
6.1Liability Insurance. Provider shall obtain and maintain, and shall cause the Pharmacies to obtain and maintain, in full force and effect and throughout the Term of this Agreement, such policies of general liability, professional liability and other insurance of the types and amounts as are reasonably and customarily carried by pharmacies with respect to their operations, as further set forth in the Provider Certification and the Provider Manual. Upon ESI’s request, Provider shall provide ESI with evidence of such insurance coverage satisfactory to ESI. If the insurance purchased to satisfy the requirements of this Section 6.1 is “claims made”, then Provider shall purchase an extended period of indemnity (“tail” coverage) so that ESI is protected from any and all claims brought against ESI for a period of not less than three (3) years subsequent to the date of termination of this Agreement.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			10 of 28

6.2Indemnification. Each party shall hold harmless, and indemnify the other party, including without limitation, its officers, directors, employees, and agents (“Indemnified Parties”), from and against loss, arising from any negligent acts or negligent omissions, willful or wrongful misconduct, knowing misrepresentation or breach of this Agreement by such party, its agents, officers, directors or employees as it relates to its activities performed under this Agreement; except to the extent such toss arises as a result of the Indemnified Party’s reckless or negligent acts or breach of this Agreement. The party seeking indemnification shall promptly notify the indemnifying party in writing within two (2) business days upon learning of any loss for which indemnification may be sought hereunder, and shall tender the defense related thereto, to the indemnifying party and afford the indemnifying party with a reasonable opportunity to comment on such defense. Notwithstanding anything to the contrary herein, no party shall be obligated to indemnify the other party with respect to any loss settled without the indemnifying party’s written consent.
7.MISCELLANEOUS PROVISIONS.
7.1Contacting Sponsors, Members or Media. Provider hereby agrees (and shall cause its affiliates, employees, independent contractors, shareholders, members, officers, directors and agents to agree) that it shall not, directly or indirectly, verbally or in writing: (i) engage in any contact or outreach to any Sponsor and/or Sponsor’s Member; (ii) make any public statements, including, but not limited to, statements to the media, press releases, postings to any social media site, publishing information on the internet, or otherwise disseminating information regarding this Agreement, ESI, ESI’s Sponsors, or ESI’s services without the prior consent of ESI; or (iii) take any action which is intended to or would be expected to harm ESI or ESI’s reputation, or which could reasonably be expected to lead to unwanted or unfavorable publicity relating to ESI or ESI’s services. Notwithstanding the foregoing, Provider may contact Sponsor’s Members for the sole purpose of carrying out generally accepted pharmacy practice (e.g., informing a Sponsor’s Member that a prescription is ready for pick up). Further, Provider acknowledges and agrees that any breach of this Section 7.1 by Provider (or any affiliate, employee, independent contractor, shareholder, member, officer, director or agent) would cause ESI immediate and irreparable injury or loss that cannot be fully remedied by monetary damages. Accordingly, in the event of a breach of this Section 7.1 by Provider (or any affiliate, employee, independent contractor, shareholder, member, officer, director or agent), ESI shall be entitled to specific performance, including immediate issuance of a temporary restraining order or preliminary injunction enforcing the terms of this Agreement, and to judgment for damages (including reasonable attorneys’ fees and costs) caused by the breach, and to all other legal and equitable remedies available to ESI. This Section 7.1 shall survive termination or expiration of the Agreement for any reason.
7.2Notice. Except as otherwise provided in this Agreement, any notice required to be given pursuant to the terms and conditions of this Agreement shall be in writing and: (a) delivered in person, evidenced by a signed receipt; (b) deposited in the United States mail, certified or registered, return receipt requested (or other similar method of delivery with a nationally recognized carrier (e.g., FedEx, UPS)); (c) delivered by facsimile, evidenced by a transmission receipt; or (d) delivered by email transmission to the email address listed below, as evidenced by a copy of the successful email transmission displaying such email address, to ESI or the Provider at the address set forth below or (e) to the last address or fax number or email address subsequently reported in writing to the respective party:
						
	If to ESI:	The street address and/or email address as set forth in the Notices section of the Provider Manual.
		
	If to Provider:	6665 Millcreek Dr. Unit 1
		Mississauga, ON
		LSN 5M4
		Attention:  Legal Department
		Email:  jgalati@medavail.com
		

THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			11 of 28

Notice will be deemed received on (f) the date of delivery if the notice is personally delivered, sent via certified or registered mail, return receipt requested (or other similar method of delivery with a nationally recognized carrier), sent via facsimile or email transmission, or (g) the third business day after the date of mailing of the notice is mailed by United States mail. Notwithstanding the foregoing, ESI may give notice to Provider (or any Pharmacy) via its online claims system or in any remittance advice.
7.3Entire Agreement. This Agreement, including any applicable rate sheets, exhibits, amendments, appendices, Provider Certification, the Express Scripts, Inc. State of Washington Pharmacy Provider Agreement for Washington State Sponsors (if applicable), addenda (including the Medicare Part D Addendum), Provider Manual, and any requirements of a Sponsor’s Prescription Drug Program communicated to Provider constitutes the entire agreement of the parties with respect to the subject matter herein and, upon execution by the parties, supersedes all prior oral or written agreements between the parties with respect to the subject matter hereof. With the exceptions of federal, state and/or Sponsor-­specific requirements as set forth in the appendices of the Provider Manual, in the event of any conflict between the terms and conditions of this Agreement and the Provider Manual, the terms of this Agreement shall prevail. Notwithstanding the foregoing sentence, solely with respect to services rendered in the state of New York under this Agreement to any Member of any Prescription Drug Program offered by a Sponsor that is certified as a managed care organization under Article 44 of the New York State Public Health Law, in the event of any conflict between the terms and conditions of this Agreement and the Provider Manual, the terms of this Agreement shall prevail.
7.4Amendment. Unless prohibited or modified by existing law, ESI may amend any term, part or provision of this Agreement, including without limitation, any exhibits, requirements for participation, schedules, amendments, or addenda (including an amendment required due to a change in law, rule or regulation), by giving written notice to Provider at least ten (10) calendar days prior to the Effective Date of the amendment ("Notice Period"). Provider shall be deemed to have accepted such amendment in the event it fails to provide written notice of its objection to ESI prior to the expiration of the Notice Period. If Provider continues to submit claims after the effective date of any proposed amendment, then such amendment will be deemed approved and accepted by Provider as if Provider had given its express written consent thereto, and such amendment shall automatically become a part of this Agreement. In the event Provider rejects such amendment in accordance herewith, then Provider may terminate this Agreement by giving written notice of such election to ESI on or before the expiration of the Notice Period, and such termination shall be effective ninety (90) days from the expiration of the Notice Period. In the event Provider rejects such amendment but does not terminate this Agreement on or before the expiration of the Notice Period, then the amendment will be deemed approved and accepted by Provider as if Provider had given its express written consent thereto, and such amendment shall automatically become a part of this Agreement and take effect as of the expiration of the Notice Period. Solely with respect to changes that affect Provider compensation, in the event Provider rejects the proposed amendment, then Provider and ESI agree to negotiate up to thirty (30) days in good faith a mutually agreeable resolution (“Good Faith Negotiations”). In the event parties cannot come to a mutually agreeable resolution, then ESI reserves the right to proceed with implementation of the amendment upon expiration of the Good Faith Negotiations period, or Provider may terminate this Agreement in accordance with this Section 7.4. Notwithstanding the foregoing, and only to the extent a signature is required or requested by ESI, the parties acknowledge and agree that any contract document, including, but not limited to, rate exhibits, schedules, letters of agreement, etc., proposed by ESI and executed by Provider hereafter shall automatically become incorporated into this Agreement without the necessity of a formal amendment.
7.5Assignment. No part of this Agreement may be assigned by Provider without ESI's prior written consent. Provider acknowledges and agrees that ESI, without consent of Provider, may assign all or any part of this Agreement and/or ESI's rights, privileges or duties under this Agreement.
7.6Force Majeure. Any party’s delay in, or failure of, performance under this Agreement shall be excused where such delay or failure is the result of causes that are beyond the reasonable control of the affected party, including acts of God (e.g., nature, fire, flood, etc.), terrorism, war, civil disturbance, court order, governmental intervention, epidemic, pandemic, failures or fluctuations in electrical power, heat, light, air conditioning, computer, software, communications, transmission or mechanical failure, work stoppage, delays or failure to 
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			12 of 28

act, or other catastrophe beyond a party’s reasonable control. In such an event, the parties will use commercially reasonable efforts to resume performance as soon as reasonably possible under the circumstances giving rise to the party’s failure to perform. Both ESI and Provider will use joint communication and resources to assist the other party in the event of a Force Majeure.
7.7Headings. The article and section headings contained in this Agreement are for convenience only and will in no manner be construed as part of this Agreement.
7.8Governing Law. This Agreement shall be construed and governed in all respects according to the internal laws in the State of Missouri, without regard to conflict of law principles. Notwithstanding the foregoing sentence, solely with respect to services rendered in the state of New York under this Agreement to any Member of any Prescription Drug Program offered by a Sponsor that is certified as a managed care organization under Article 44 of the New York State Public Health Law, this Agreement shall be construed and governed in all respects according to the internal laws in the State of New York, without regard to conflict of law principles.
7.9Waiver. No waiver of a breach of any covenant or condition shall be construed to be a waiver of any subsequent breach. No act, delay, or omission done, suffered, or permitted by the parties shall be deemed to exhaust or impair any right, remedy, or power of the parties hereunder.
7.10Severability. Should any provision of this Agreement be held or ruled unenforceable or ineffective under the law, such a ruling will in no way affect the validity or enforceability of any other clause or provision contained herein.
7.11Non-Competition. Provider agrees during the Term of this Agreement and for a period of one (1) year thereafter it will not use any of the information it obtains pursuant to this Agreement or as a result of providing services hereunder, to its benefit or for the benefit of any of its affiliates or Pharmacies, including to solicit any of the Sponsors for which Provider provided services to Members of such Sponsors during the Term of this Agreement.
7.12Dispute Resolution. Except as provided herein, prior to either party pursuing any litigation in connection with this Agreement, both parties agree to meet in good faith to resolve any claim or controversy (“Claim”), whether under federal or state statutory or common law, brought by either ESI or the Provider against the other, or against the employee, members, agents or assigns of the other, arising from or relating in any way to the interpretation or performance of this Agreement. The aggrieved party shall notify the other party of its Claim providing sufficient detail to permit the other party to respond. The parties agree to meet and confer in good faith to resolve any Claims that may arise under this Agreement for a period of not less than thirty (30) days. In the event the parties cannot resolve any Claims pursuant to Good Faith Discussions and the minimum 30-day period has been met, then the aggrieved party may end discussions with the other party by providing written notice to the other party of its intent to cease discussions. Thereafter, the parties may proceed to litigation. Good Faith Discussion and the 30-day notice period do not apply to Claims by either party solely seeking immediate injunctive relief. The prevailing party on any Claim(s) seeking injunctive relief relating to the term or termination of this Agreement shall be entitled to its reasonable attorneys’ fees and costs. All litigation between the parties arising out of or related in any way to the interpretation or performance of the Agreement shall be litigated in the U.S. District Court for the Eastern District of Missouri, or, as to those lawsuits to which the Federal Court lacks jurisdiction, before a court located in St. Louis County, Missouri. The parties agree that Claims shall not be consolidated or coordinated in any action with the Claim of any other individual or entity. No Claim or other dispute may be litigated on a coordinated, class, mass, or consolidated basis. No Claim may be brought as a private attorney general.
7.13Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original and together will constitute one and the same Agreement. Facsimile execution and delivery of this Agreement is legal, valid and binding execution and delivery for all purposes.
7.14Incorporation of Recitals. The recitals are hereby incorporated into and made a part of this Agreement.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			13 of 28

7.15Survival. Notwithstanding anything herein to the contrary, all provisions intended to survive the expiration or termination of this Agreement, including the Provider Manual, shall survive such expiration or termination for any reason.
7.16Incorporation of NY Standard Clauses. As required by the New York State Department of Health, solely with respect to services rendered in the state of New York under this Agreement to any Member of any Prescription Drug Program offered by a Sponsor that is certified as a managed care organization under Article 44 of the New York Public Health Law, the New York State Department of Health Standard Clauses for Managed Care Provider/IPA Contracts ("NY Standard Clauses"), as set forth in Appendix 1, shall be and are expressly incorporated and adopted herein by reference. Solely with respect to the same services, to the extent of any inconsistency between the NY Standard Clauses and other provisions of this Agreement, the provision of the NY Standard Clauses shall control, except to the extent applicable law requires otherwise and/or to the extent a provision of this Agreement exceeds the minimum requirements of the NY Standard Clauses.
7.17Authority to Enter into Agreement; Legal Agreement. Each party represents and warrants to the other that: (a) it has all requisite corporate power and authority to enter into this Agreement and perform all obligations required to be performed by such party under this Agreement; (b) neither its execution and delivery of this Agreement nor the performance of its obligations by such party under this Agreement will conflict with, or result in a breach of any covenant or agreement between it and any third party; and (c) this Agreement together with its Exhibits (as applicable) represents its legal, valid and binding obligation.
7.18Authority to Sign. By signing this Agreement, the individual represents and warrants that such individual has the authority to so bind the entity for which it is signing this Agreement.
[SIGNATURE PAGE FOLLOWS]
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			14 of 28

IN WITNESS WHEREOF, the parties have executed and entered into this Agreement as of the date set forth below.
									
	ACCEPTED:
		
			
	MedAvail Pharmacy INC. dba APM Pharmacy		EXPRESS SCRIPTS, INC.
			
			
	Signature:  /s/ Ed Kilroy		Signature:  /s/ Wendy L. Barnes
			
	Printed Name:  Ed Kilroy		Wendy L. Barnes, Vice President and General Manager
			
	Title:  CEO		Retail Network Management
			
	Date:  9/11/2017		Date:
			
	Chain Code or NCPDP: 0361725		
			
	Contract No.: NCM367884		
			
			DIVERSIFIED IPA (NY), INC.
			
			Signature:  /s/ Wendy L. Barnes
			
			Wendy L. Barnes, Vice President and General Manager
			
			Retail Network Management
			
			Date:
			

Please Fax Entire Document to: 877.387.5800
FOIA NOTICE: This document contains Express Scripts, Inc. proprietary information and/or data. Recipient, by accepting this document, agrees that it will not duplicate, use, or disclose-in whole or in part-this document, or the information contained therein, or any part thereof to others for any other purpose except as specifically authorized in writing by Express Scripts, Inc. EXEMPT FROM PUBLIC DISCLOSURE: Information contained herein is confidential information of Express Scripts, Inc. and is exempt from public disclosure under 5 U.S.C. §552(b). Do not disclose outside of the recipient organization of the United States Government.
NO ALTERATIONS TO THIS DOCUMENT SHALL BE BINDING UNLESS INITIALED BY DULY AUTHORIZED REPRESENTATIVES OF PROVIDER AND ESI.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
	Notice: certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.		1 of 5

EXHIBIT A – ES1000K
As of the Rate Effective Date (as defined in Section 1), the terms for reimbursement for the network product(s) set forth in this Exhibit A – ES1000K (the “Exhibit”) shall be the terms for reimbursement then in effect between Express Scripts, Inc. (“ESI”) and Provider for the network configurations described herein.
1.Definitions.
1.1“ESI MAC” means the maximum allowable cost for such drugs as determined by ESI. The items and their prices will be updated by ESI from time to time at its sole discretion.
1.2“Rate Effective Date” means the last date upon which ESI accepts and processes this Exhibit.
2.Provider Reimbursement for Covered Medications.
2.1For Covered Medications dispensed to Members under this Exhibit, Provider shall receive reimbursement equal to the lowest of the following (subject to the overall annual Average Discounts and Dispense Fees set forth in Section 2.4 as further described below):
(a)the Provider's Usual and Customary Retail Price;
(b)the applicable AWP discount plus applicable dispensing fee as set forth in Section 2.4
(or per the applicable Supplemental Schedule);
(c)the Provider's submitted ingredient cost plus applicable dispensing fee;
(d)ESI MAC (if applicable) plus applicable dispensing fee; or
(e)state fee schedule (if applicable).
2.2The parties acknowledge and agree that more than one AWP discount and/or dispense fee may be in effect and applied from time to time to claims submitted by Provider under the terms of this Exhibit. The annual effective Average Discount and Dispense Fee guarantees specified below in Section 2.4 are not Sponsor-­specific claims adjudication rates. Rather, claims shall be adjudicated by ESI based on the applicable Supplemental Schedule referenced below in Section 2.3, provided, ESI shall be obligated to manage to the overall annual effective rate guarantees as referenced below in Section 2.4 on an aggregate basis for its applicable book of business. The overall Average Discount and Dispense Fee for any given Year shall ultimately be the AWP discount and dispense fee set forth in the Contract Rates table for the applicable Schedule as set forth below in Section 2.4. The overall Average Discounts and Dispense Fees set forth in Section 2.4 of this Exhibit (with the exception of Schedule MEDD) (the "Commercial Aggregate") plus the overall average Transaction Fee set forth in the Agreement, as applicable, for claims submitted under the terms of all commercial (non-Medicare) rate sheets under the Agreement shall be calculated in aggregate based on ESI's entire applicable book of business. As applicable, the Schedule MEDD overall Average Discount and Dispense Fee set forth in Section 2.4 of this Exhibit shall be calculated in aggregate for ESI’s entire applicable book of business (the “Med D Aggregate”). The Commercial Aggregate and the Med D Aggregate, as applicable, shall not themselves be aggregated; and the Commercial Aggregate and the Med D Aggregate, as applicable, shall not be aggregated at a Sponsor-specific level.
2.3ESI shall establish and maintain specific reimbursement rate schedules (each, a “Supplemental Schedule”, and collectively, the “Supplemental Schedules”), which shall not require Provider signature for each particular Supplemental Schedule, and shall constitute the applicable AWP Discounts and Dispense Fees applied to the adjudicated prescription drug claims related to a particular Sponsor, or group of Sponsors and which Sponsor(s) may or may not be individually listed on a Supplemental Schedule. Each Supplemental Schedule is incorporated herein by reference. The form of the Supplemental Schedule template to be used generally by ESI is set forth on Supplement A, attached hereto and incorporated herein by this reference.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			2 of 5

2.4Contract Rates tables:
2.4.aSchedule A Contract Rates: Any non-Medicare network configuration(s).
												
		BRANDS	GENERICS – A
	GENERICS – B

		Up to an Average Discount Single-Source & Multi-Source(3.1) Brands not paid on ESI MAC + Not less than an Average Dispensing Fee:
	Up to an Average Discount Generic Drugs not paid on ESI MAC + Not less than an Average Dispensing Fee:	Generic Drugs and Multi-Source Brands paid on ESI MAC + Not less than an Average Dispensing Fee:
	30 Day (3.3)
	AWP – [__________]
	AWP – [__________]
	ESI MAC + [____]

	90 Day (3.3)
	AWP - [__________]
	AWP - [__________]
	ESI MAC + [____]

2.4.bSchedule MEDD Contract Rates: ESI’s broadest, open access Medicare Part D network of providers. For clarification, regarding the applicability of the Schedule MEDD Contract Rates, ESI’s Medicare Part D network of providers may be offered to one or more of a Sponsor's benefit plans, including, but not limited to, MA-PD and MA-PDP plans, Medicare-Medicaid Program ("MMP") plans, and/or other qualified plans, consistent with applicable law.
												
		BRANDS	GENERICS – A
	GENERICS – B

		Up to an Average Discount Single-Source & Multi-Source(3.1) Brands not paid on ESI MAC + Not less than an Average Dispensing Fee:
	Up to an Average Discount Generic Drugs not paid on ESI MAC + Not less than an Average Dispensing Fee:	Generic Drugs and Multi-Source Brands paid on ESI MAC + Not less than an Average Dispensing Fee:
	30 Day	AWP – [__________]
	AWP – [__________]
	ESI MAC + [____]

	90 Day	AWP - [__________]
	AWP - [__________]
	ESI MAC + [____]

3.Notes.
3.1Multi-Source pricing depends on the DAW Code utilized and design of the specific Prescription Drug Program.
3.2All payments shall be net of the applicable Copayment.
3.3If Sponsor chooses a benefit design that covers extended days supply (“EDS”), then generally, unless otherwise directed by Sponsor, for non-Medicare Part D claims, as applicable, 30-day rate covers 1-83 days and 90-day rate covers 84-90+ days; and for Medicare Part D claims, as applicable, 30-day rate covers 1-34 days and EDS covers 35+ days.
3.4Both parties acknowledge and agree that (i) Provider’s participation in one or more Schedule(s) or Sponsor network configuration(s), shall be as determined by Sponsor or ESI; (ii) Provider’s reimbursement rates set forth herein may be applied to network configurations in order to meet network access requirements and/or to meet the needs of a specific Sponsor or population, as determined by ESI at its sole discretion; and (iii) nothing in this Exhibit shall guarantee Provider’s participation in a particular Schedule or network configuration. Further, unless otherwise specified, any network configuration under Section 2.4 may be utilized as an exclusive or preferred network configuration. Preferred network configurations will require that a Sponsor electing a preferred option implement a plan design that imposes a Copayment differential between preferred and non-preferred providers.
3.5Provider acknowledges and agrees that it shall not submit claims to any other processor or administrator when documentation confirms the Member's positive eligibility with ESI or an organization contracted with ESI.
3.6Provider acknowledges and agrees that Provider shall provide services hereunder in accordance with any and all applicable state rules, regulations and guidance, including the terms and conditions contained in the Appendix A - State Legal Requirements and Medicaid sections of the Provider Manual, as applicable.
4.Term and Termination.
4.1This Exhibit and the rates contained herein are subject to the terms and conditions of the Agreement.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			3 of 5

4.2This Exhibit shall automatically terminate upon the termination of the Agreement.
5.Transaction Charges.  Provider or Pharmacy is solely responsible for all transaction charges for claims transmitted to ESI that go through any mutually agreeable electronic switch.
[SUPPLEMENTAL SCHEDULE FOLLOWS]
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			4 of 5

SCHEDULE xxx
FORM OF SUPPLEMENTAL SCHEDULE TEMPLATE
Notwithstanding anything to the contrary in the Agreement or the applicable Exhibit A, the term of this Schedule shall commence on the Schedule Effective Date (as defined in Section 3) and continue thereafter, subject to change per the Agreement.
1.Pharmacy Reimbursement Rates For Covered Medications. For Covered Medications dispensed to Members, Provider shall receive reimbursement equal to the lowest of the following, at the rates in the Contract Rates table below:
(1)For Single-Source and Multi-Source Brands and Generic Drugs without an ESI MAC:
(a)the Provider's Usual and Customary Retail Price;
(b)not less than the applicable AWP discount plus dispensing fee;
(c)the Provider's submitted ingredient cost plus dispensing fee; or
(d)the state fee schedule (if applicable).
(2)For Generic Drugs and Multi-Source Brands with an ESI MAC:
(a)the Provider's Usual and Customary Retail Price;
(b)not less than the applicable AWP discount plus dispensing fee
(as listed under the "BRANDS” column or the "GENERICS - A” column);
(c)an ESI MAC plus dispensing fee;
(d)the Provider's submitted ingredient cost plus dispensing fee; or
(e)the state fee schedule (if applicable).
												
		BRANDS	GENERICS - A	GENERICS - B
		Single-Source & Multi-Source(2.1) Brands not paid on ESI MAC(2.2)
	Generic Drugs not paid on ESI MAC	Generic Drugs and Multi-Source Brands paid on ESI MAC
	30 Day	AWP - % + $	AWP - % + $	ESI MAC + $
	90 Day	AWP- % + $	AWP - % + $	ESI MAC + $

2.Notes.
2.1Multi-Source pricing depends on the DAW Code utilized and design of the specific Prescription Drug Program.
2.2“ESI MAC" means the maximum allowable cost for such drugs as determined by ESI. The items and their prices will be updated by ESI from time to time at its sole discretion.
2.3All payments shall be net of the applicable Copayment.
3.Schedule Effective Date. The reimbursement rates set forth herein shall become effective (INSERT DATE] (the "Schedule Effective Date").
AS REASONABLY MODIFIED FROM TIME-TO-TIME BY ESI TO REFLECT SPECIFIC RATES
[END OF SCHEDULE xxx]
[SIGNATURE PAGE FOLLOWS]
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

									
			5 of 5

[SIGNATURE PAGE TO EXHIBIT A - ES1000K]
									
			
		Chain Code(s):	
			
		Pharmacy Name:  MEDAVAIL PHARMACY, INC. d/b/a APM PHARMACY	
			
			
		This section is to be completed by a duly authorized representative:	
			
		Signature:  /s/ Ed Kilroy
	
			
		Printed Name:  Ed Kilroy
	
			
		Date:  9/11/2017
	

Please Fax Entire Document to: 877.387.5800
FOIA NOTICE: This document contains Express Scripts, Inc. proprietary information and/or data. Recipient, by accepting this document, agrees that it will not duplicate, use, or disclose-in whole or in part-this document, or the information contained therein, or any part thereof to others for any other purpose except as specifically authorized in writing by Express Scripts, Inc. EXEMPT FROM PUBLIC DISCLOSURE: Information contained herein is confidential information of Express Scripts. Inc. and is exempt from public disclosure under 5 U.S.C. §552(b). Do not disclose outside of the recipient organization of the United States Government.
NO ALTERATIONS TO THIS DOCUMENT SHALL BE BINDING UNLESS INITIALED BY DULY AUTHORIZED REPRESENTATIVES OF PROVIDER AND ESI.
THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION PROTECTED FROM PUBLIC DISCLOSURE UNDER 5 U.S.C. § 552 (b).
PLEASE READ THE FULL "FOIA NOTICE" ON THE SIGNATURE PAGE AND/OR THE FIRST PAGE OF THIS DOCUMENT.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]